Accumulation of specific amino acid substitutions in HLA-B35-restricted human immunodeficiency virus type 1 cytotoxic T lymphocyte epitopes

AIDS Research and Human Retroviruses

Volumn 15, Issue 12, 1999, Pages 1099-1107

  Kawana, Ai ^a   Tomiyama, Hiroko ^b   Takiguchi, Masafumi ^b   Shioda, Tatsuo ^a   Nakamura, Tetsuya ^a   Iwamoto, Aikichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA B35 ANTIGEN;

AMINO ACID SUBSTITUTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS MUTATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CLONE CELLS; DNA PRIMERS; EPITOPES; HIV-1; HLA-B35 ANTIGEN; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033543115     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310395     Document Type: Article

References (29)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
3. Hoffenbach A, Langlade DP, Dadaglio G, Vilmer E, Michel F, Mayaud C, Autran B, and Plata F: Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989;142:452-462.
4. Klein MR, van BC, Holwerda AM, Kerkhof GS, Bende RJ, Keet IP, Eeftinck SJ, Osterhaus AD, Schuitemaker H, and Miedema F: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of raid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365-1372.
5. Moss PA, Rowland JS, Frodsham PM, McAdam S, Giangrande P, McMichael AJ, and Bell JI: Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci USA 1995;92: 5773-5777.
6. Oldstone MB: HIV versus cytotoxic T lymphocytes-the war being lost. N Engl J Med 1997;337:1306-1308.
7. Nowak MA, May RM, Phillips RE, Rowland JS, Lalloo DG, McAdam S, Klenerman P, Koppe B, Sigmund K, Bangham CR, et al.: Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature (London) 1995;375:606-611.
8. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, and Safrit JT: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-542.
9. Haynes BF, Pantaleo G, and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
10. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, and Mann DL: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med 1996;2:405-411.
11. Sahmoud T, Laurian Y, Gazengel C, Sultan Y, Gautreau C, and Costagliola D: Progression to AIDS in French haemophiliacs: Association with HLA-B35. AIDS 1993;7:497-500.
12. Itescu S, Rose S, Dwyer E, and Winchester R: Grouping HLA-B locus serologic specificities according to shared structural motifs suggests that different peptide-anchoring pockets may have contrasting influences on the course of HTV-1 infection. Hum Immunol 1995;42:81-89.
13. Shiga H, Shioda T, Tomiyama H, Takamiya Y, Oka S, Kimura S, Yamaguchi Y, Gojoubori T, Rammensee HG, Miwa K, and Takiguchi M: Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS 1996;10:1075-1083.
14. Tomiyama H, Miwa K, Shiga H, Moore YI, Oka S, Iwamoto A, Kaneko Y, and Takiguchi M: Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J Immunol 1997;158:5026-5034.
15. Ausbel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl K: Mutagenesis by the polymerase chain reaction. In: Current Protocols in Molecular Biology, Vol. 1. Greene Publishing Associates and Wiley-Interscience, 1994, pp. 8.5.1-8.5.9.
16. Shioda T and Shibuta H: Production of human immunodeficiency virus (HIV) like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 1990; 175:139-148.
17. Takiguchi M, Kawaguchi G, Sekimata M, Hiraiwa M, Kariyone A, and Takamiya Y: The role of the conserved residue in pocket A and the polymorphic residue in pocket E of HLA-B*3501 in presentation of human minor histocompatibility peptides to T cells. Int Immunol 1994;6:1345-1352.
18. Ooba T, Hayashi H, Karaki S, Tanabe M, Kano K, and Takiguchi M: The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two genetic mechanisms. Immunogenetics 1989;30: 76-80.
19. Myers G, Korber B, Hahn BH, Jeang K-T, Mellors JW, McCutchan FE, Henderson LE, and Pavlakis GN: A complication and analysis of nucleic acid and amino acid sequences. In: Human Retroviruses and AIDS 1995. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
20. Popovic M, Sarngadharan MG, Read E, and Gallo RC: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
21. Pircher H, Moskophidis D, Rohrer U, Burki K, Hengartner H, and Zinkernagel RM: Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (London) 1990;346:629-633.
22. Aebischer T, Moskophidis D, Rohrer UH, Zinkernagel RM, and Hengartner H: In vitro selection of lymphocytic choriomeningitis virus escape mutants by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1991;88:11047-11051.
23. de Campos-Lima PO, Levitsky V, Brooks J, Lee SP, Hu LF, Rickinson AB, and Masucci MG: T cell responses and virus evolution: Loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly All-positive populations by selective mutation of anchor residues. J Exp Med 1994;179:1297-1305.
24. Phillips RE, Rowland JS, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR, et al.: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (London) 1991;354:453-459.
25. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJ, Simmonds P, Morrison H, and Jones M: HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988;1:1185-1188.
26. Kaslow RA, Duquesnoy R, VanRaden M, Kingsley L, Marrari M, Friedman H, Su S, Saah AJ, Detels R, Phair J, et al.: A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet 1990;335:927-930.
27. Haas G, Plikat U, Debre P, Lucchiari M, Katlama C, Dudoit Y, Bonduelle O, Bauer M, Ihlenfeldt H-G, Jung G, Maier B, Meyerhans A, and Autran B: Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol 1996;157:4212-4221.
28. Meyerhans A, Dadaglio G, Vartanian JP, Langlade DP, Frank R, Åsjö B, Plata F, and Wain HS: In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol 1991;21: 2637-2640.
29. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.